Related content

Phase I Pharmacokinetic Study of Nivolumab in Korean Patients with Advanced Solid Tumors

By  

The Oncologist, Vol. 23, Iss. 2, 2018-02 ,pp. : 155-e17

John Wiley & Sons Inc

Access to resources Recommend Favorite

A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound, administered as a 24-h continuous infusion in patients with advanced solid tumors

By Gordon Michael   Ilaria Robert   Alwis Dinesh   Mendelson David   McKane Scott   Wagner Margaret   Look Katherine   LoRusso Patricia  

Cancer Chemotherapy and Pharmacology, Vol. 71, Iss. 1, 2013-01 ,pp. : 21-27

Springer Publishing Company

Access to resources Recommend Favorite

Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours

By Trocòniz Iñaki   Garrido María   Segura Cristina   Cendrós Josep-María   Principe Paola   Peraire Concepción   Obach Rosendo  

Cancer Chemotherapy and Pharmacology, Vol. 57, Iss. 6, 2006-06 ,pp. : 727-735

Springer Publishing Company

Access to resources Recommend Favorite

A phase I, pharmacokinetic and pharmacodynamic study of nimotuzumab in Japanese patients with advanced solid tumors

By Okamoto Wataru   Yoshino Takayuki   Takahashi Toshiaki   Okamoto Isamu   Ueda Shinya   Tsuya Asuka   Boku Narikazu   Nishio Kazuto   Fukuoka Masahiro   Yamamoto Nobuyuki   Nakagawa Kazuhiko  

Cancer Chemotherapy and Pharmacology, Vol. 72, Iss. 5, 2013-11 ,pp. : 1063-1071

Springer Publishing Company

Access to resources Recommend Favorite

A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors

By Hurwitz Herbert   Cohen Roger   McGovren J.   Hirawat Samit   Petros William   Natsumeda Yutaka   Yoshinari Tomoko  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 1, 2007-01 ,pp. : 139-147

Springer Publishing Company

Access to resources Recommend Favorite